Clinical Trial Search block Test

PEDIATRIC AND YOUNG ADULT LEUKEMIA ADOPTIVE THERAPY (PLAT)-07: A PHASE 1/2 STUDY OF CD22-SPECIFIC CAR T CELLS FOR CD22+ LEUKEMIA OR LYMPHOMA

PLAT-07

  • Condition(s): Acute Lymphoblastic Leukemia (ALL), Infant Leukemia, Leukemia & Lymphoma, Lymphoblastic Lymphoma (LBL), Non-Hodgkin Lymphoma (NHL), Recurrent and/or Refractory
  • Phase: I/II
  • Clinicaltrials.gov ID: NCT04571138

What is the goal of the study?

This phase 1/2, open-label, non-randomized study will enroll pediatric and young adult research participants with relapsed or refractory CD22+ leukemia or lymphoma with and without prior history of allogeneic hematopoietic stem cell transplantation, to examine the safety, feasibility, and efficacy of administering T cell products derived from autologous peripheral blood mononuclear cells (PBMC) that have been genetically modified using a self-inactivating SIN lentiviral vector to express a CD22-specific chimeric antigen receptor (CAR), and the selection-suicide marker EGFRt (SCRI-CAR22v2).

Who can participate in the study?

Everyone

Study Team: